New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 25, 2013
07:18 EDTRNN, INO, BAXS, VSCI, PCRX, GENT, RPRX, LMAT, CRISBrean Capital to hold a summit
2013 Life Sciences Summit is being held in New York on November 25.
News For BAXS;CRIS;GENT;INO;LMAT;PCRX;RNN;RPRX;VSCI From The Last 14 Days
Check below for free stories on BAXS;CRIS;GENT;INO;LMAT;PCRX;RNN;RPRX;VSCI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2014
07:37 EDTBAXSBaxano Surgical receives FDA clearance for Avance MIS Pedicle Screw System
Subscribe for More Information
April 9, 2014
08:24 EDTBAXSPiper Jaffray's medtech analysts hold an analyst/industry conference call
The MedTech Analyst Team focuses on Piper Jaffray's covered universe from the perspective of Technical Analyst Johnson ahead of 1Q14 earnings results on an Analyst/Industry conference call to be held on April 11 at 10 am.
April 8, 2014
19:57 EDTPCRXPacira Pharmaceuticals 1.6M share Spot Secondary priced at $64.00
Subscribe for More Information
07:22 EDTCRISBiotech Industry Organization to hold a conference
Subscribe for More Information
April 7, 2014
16:35 EDTPCRXPacira Pharmaceuticals files to sell $100M of common stock
Subscribe for More Information
16:14 EDTCRISCuris reports CUDC-907, CUDC-427 data
Subscribe for More Information
16:11 EDTCRISCuris, Debiopharm Group report preclinical data for Debio 0932
Curis and Debiopharm Group announced the presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research, or AACR, that demonstrated synergy between Debio 0932 and various standard of care, or SOC, agents in multiple in vitro and xenograft models of non-small cell lung cancer, or NSCLC, and renal cell carcinoma, or RCC. Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in a Phase 1 trial in combination with everolimus, a mTOR inhibitor, in advanced RCC patients. In a high throughput combination screen performed with six different human NSCLC cell lines, Debio 0932 demonstrated consistent synergy with microtubule and mTOR/ Akt targeting agents across all six cell lines. Additionally, Debio 0932 also showed strong synergy with everolimus in multiple patient derived and conventional RCC cell lines. Similar synergy and anti-tumor activity with Debio 0932 in combination with these agents was also demonstrated in human xenograft models of NSCLC and RCC.
16:08 EDTPCRXPacira Pharmaceuticals files automatic mixed securities shelf
Subscribe for More Information
16:04 EDTPCRXPacira Pharmaceuticals enters co-production partnership with Patheon
Subscribe for More Information
April 4, 2014
16:31 EDTPCRXPacira Pharmaceuticals reports additional Phase 3 data supporting EXPAREL
Subscribe for More Information
April 2, 2014
09:09 EDTRNNRexahn expects to complete Phase 1 Supinoxin trial in 4Q14
Subscribe for More Information
09:07 EDTRNNRexahn reports FY13 total operating expenses $8M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use